Human Vaccines Market Research Report - Middle East and Africa Forecast to 2027

Middle East and Africa Human Vaccines Market Information, by Technology (Attenuated, Inactivated, Toxoid, Conjugate, & Subunit, Recombinant DNA), Disease Indication (Pneumococcal, Influenza, Hepatitis, Rotavirus, DTP, Polio, others), by Type (Prophylactic and Therapeutic); by Composition (Mono Vaccine and Combination Vaccines) by End User (children and adults) and by Route of Administration (Oral, Injectable And Other) - Forecast till 2027

ID: MRFR/Pharma/1984-HCR | February 2021 | Region: Middle East & Africa | 84 pages

Please note that the assessment period of report has been updated from 2013- 2022 to 2020-2027. Cordially fill Sample form for updated data.

Impact of Covid-19 on Human Vaccine Market


COVID-19 is a respiratory ailment caused by coronavirus. Currently, the world is facing a pandemic due to this disease. The pandemic has posed a positive as well as a negative impact on the human vaccines market.


There is no existing vaccine available for the prevention of the disease, and biotechnology and pharmaceutical companies are investing huge amounts on the R&D of a human vaccine for the prevention of COVID-19. For instance, on 7 May 2020, Moderna, a US-based company that has a vast and innovative pipeline of mRNA- based vaccines for the treatment of various diseases, received the US Food and Drug Administration’s (FDA) approval for its investigational new drug (IND) application for mRNA-1273 and proceeding it for the phase-2 clinical trials. The company received funding for its phase-1 clinical trial’s vaccine batch from the Coalition for Epidemic Preparedness and Innovation (CEPI). On 16 April 2020, the company had also received an award of USD 483 million from the BARDA, a US government agency, for accelerating the development of mRNA-1273. Furthermore, on May 1, 2020, Moderna also signed a strategic collaboration with Lonza to manufacture mRNA-1273 and enable manufacturing of up to 1 billion doses per year, which is said to be enough for over one-eighth of the world’ population. This has caused a positive impact on the market.


The pandemic has also resulted in a lot of acquisitions, mergers, and collaborations for the development of a vaccine, which has accelerated the growth of the human vaccines market tremendously. For instance, in April 2020, AstraZeneca collaborated with the University of Oxford for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing the infection of SARS-CoV-2. This collaboration aimed to bring to patients the potential vaccine known as ChAdOx1 nCoV-19, being developed by the Jenner Institute and Oxford Vaccine Group, at the University of Oxford. Under the agreement, AstraZeneca would be responsible for the development and worldwide manufacturing and distribution of the vaccine.


The demand for vaccines, such as the Bacillus Calmette-Guerin (BCG), is also expected to increase as it was reported by experts that the vaccine  is effective for the prevention of COVID-19. For instance, on 6 April 2020, scientists in Melbourne, Australia, started administering the BCG vaccine or a placebo to thousands of physicians, nurses, respiratory therapists, and other healthcare workers. This program was the first of the several randomized controlled trials intended for testing the vaccine’s effectiveness against the coronavirus.


The outbreak of COVID-19 has applied a lot of pressure on global vaccine manufacturer production capacities, supply chains and logistics. According to the latest report on 29 April 2020, by the United National Children’s Fund (UNICEF), there has been an approximately 70 to 80% decline in the planned vaccine shipments. This is further impacted as the capacity of the available cargo flights is also reduced. It also stated that 26 countries had been identified, which are at risk of stock-out of at least one vaccine that is included in their routine immunization programs. Moreover, as advised by the World Health Organization (WHO) and the Global Polio Eradication Initiative, vaccine campaigns have been postponed.. Some countries have also suspended their planned preventative campaigns. The routine immunization programs have also been negatively impacted. Many countries have reported a reduction in the outreach activities, as well as a reduction in the demand in consideration with the COVID-19 to reduce the risk of disease transmission.

Table of Content

1 Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure:

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porter’s Five Forces Model

4.1.1 Bargaining Power of suppliers

4.1.2 Bargaining Power of Customer

4.1.3 Intensity of Competitor’s

4.1.4 Threat of New Entrants

5 Middle East and Africa Human Vaccines Market, by Technology

5.1 Introduction

5.1.1 Attenuated

5.1.2 Inactivated

5.1.3 Toxoid

5.1.4 Conjugate and Subunit

5.1.5 Recombinant DNA

6 Middle East and Africa Human Vaccines Market, by Disease Indication

6.1 Introduction

6.1.1 Pneumococcal

6.1.2 Influenza

6.1.3 Hepatitis

6.1.4 Rotavirus

6.1.5 DTP

6.1.6 Polio

6.1.7 Others

7 Middle East and Africa Human Vaccines Market, by Type

7.1 Introduction

7.1.1 Prophylactic

7.1.2 Therapeutic

8 Middle East and Africa Human Vaccines Market, by Composition

8.1 Introduction

8.1.1 Mono vaccine and

8.1.2 Combination vaccines

9 Middle East and Africa Human Vaccines Market, by Route of Administration

9.1 Introduction

9.1.1 Oral

9.1.2 Injectible

9.1.3 Others

10 Middle East and Africa Human Vaccines Market, by End User

10.1 Introduction

10.1.1 Children

10.1.2 Adults

11 Middle East and Africa Human Vaccines Market, by Country

11.1 Introduction

11.1.2 UAE

11. 1.3 Egypt

11. 1.4 Saudi Arabia

11. 1.5 Kuwait

11. 1.6 Qatar

11. 1.7 Oman

12 Company Landscape

12.1 Introduction

12.1.1 Mergers Acquisitions

12.1.2 Collaborations

12.1.3 Release/New Product Launches

12.1.4 Other (Expansion, Updates, Partnership)

13 Company Profile

13.1 GlaxoSmithKline Plc.

13.1.1 Company Overview

13.1.2 Product/Business Segment Overview

13.1.3 Financials

13.1.4 Key Developments

13.1.5 SWOT Analysis

13.2 Merck & Co. Inc.

13.2.1 Overview

13.2.2 Product/Business Segment Overview

13.2.3 Financials

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 Pfizer, Inc.

13.3.1 Overview

13.3.2 Product/Business Segment Overview

13.3.3 Financials

13.3.4 Key Developments

13.3.5 SWOT Analysis

13.4 Sanofi Pasteur, Inc.

13.4.1 Overview

13.4.2 Product/Business Segment Overview

13.4.3 Financials

13.4.4 Key Developments

13.4.5 SWOT Analysis

13.5 AstraZeneca Plc.

13.5.1 Overview

13.5.2 Product/Business Segment Overview

13.5.3 Financials

13.5.4 Key Developments

13.5.5 SWOT Analysis

13.6 Bharat Biotech

13.6.1 Overview

13.6.2 Product/Business Segment Overview

13.6.3 Financials

13.6.4 Key Developments

13.6.5 SWOT Analysis

13.7 Shenzhen Kangtai Biological Products

13.7.1 Overview

13.7.2 Product/Business Segment Overview

13.7.3 Financials

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 Valeant Pharmaceuticals

13.8.1 Overview

13.8.2 Product/Business Segment Overview

13.8.3 Financials

13.8.4 Key Developments

13.8.5 SWOT Analysis

13.9 Emergent Biosolutions Inc.

13.9.1 Overview

13.9.2 Product/Business Segment Overview

13.9.3 Financials

13.9.4 Key Developments

13.9.5 SWOT Analysis

13.10 Astellas Pharma Inc.

13.10.1 Overview

13.10.2 Product/Business Segment Overview

13.10.3 Financials

13.10.4 Key Developments

13.10.5 SWOT Analysis

13.11 Panacea Biotec

13.11.1 Overview

13.11.2 Product/Business Segment Overview

13.11.3 Financials

13.11.4 Key Developments

13.11.5 SWOT Analysis

14 Others

15 Appendix

List of Tables

TABLE 1 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, 2020-2027 (USD MILLION)

TABLE 2 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)

TABLE 3 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2020-2027 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY COMPOSITION, 2020-2027 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY REGION, 2020-2027 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TECHNOLOGY

FIGURE 4 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY DISEASE INDICATION

FIGURE 5 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY TYPE

FIGURE 6 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY COMPOSITION

FIGURE 7 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY ROUTE OF ADMINISTRATION

FIGURE 8 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY END USER

FIGURE 9 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET, BY REGION

FIGURE 10 MIDDLE EAST AND AFRICA HUMAN VACCINES MARKET: COMPANY SHARE ANALYSIS, 2020 (%)